Table 1.
Clinical and demographic data of patients included in the study
| Mean age | Median EDSS | Course | Therapy | Steroids | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RR | SP | PP | NONE | IFN | GA | NAT | FING | MIX | AZA | ||||
| ALL | 43 y | 2.5 | 82 % | 13 % | 5 % | 31 % | 25 % | 18 % | 10 % | 12 % | 1 % | 3 % | 6 % |
| MAP + | 41 y | 2 | 81 % | 15 % | 4 % | 29 % | 27 % | 17 % | 10 % | 13 % | 0 % | 4 % | 5 % |
| MAP- | 44 y | 2.5 | 84 % | 10 % | 6 % | 32 % | 26 % | 16 % | 11 % | 13 % | 1 % | 1 % | 6 % |
RR relapsing remitting, SP secondary progressive, PP primary progressive, IFN beta interferon, GA glatiramer acetate, NAT natalizumab, FING fingolimod, MIX mitoxantrone, AZA azathioprine